69 results
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
and the strength of our supply chain;
our ability to advance any product candidate into or successfully complete any clinical trial;
our ability … , including the timing and enrollment of patients, the health of our employees and the strength of our supply chain;
our ability to advance any
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
, including the timing and enrollment of patients, the health of our employees and the strength of our supply chain;
our ability to advance any product
424B5
AKRO
Akero Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
5:21pm
of patients, the health of our employees and the strength of our supply chain;
our ability to advance any product candidate into or successfully
8-K
EX-99.2
948ne5 j0
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
wq9eq1l
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-99.2
roajy752s7
5 Jun 23
Results of Operations and Financial Condition
8:05am
424B5
ftkrmjzn1j9ips8yvr
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
EX-99.1
64kpfn5
15 May 23
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
7:19am
8-K
EX-99.1
gxhq6enlivslb13nprk
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
vsk9 t9ey8m
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
nv7dwe0
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
424B5
uh0stfb3s7zv 896j
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
l6sx8n7vn46y0u8kt7t4
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-99.2
0b9 2eewetls5u
13 Sep 22
Regulation FD Disclosure
9:07am